Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer
(MedPage Today) -- SINGAPORE -- Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with advanced EGFR-mutant non-small cell lung cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Singapore Health